Pharmacoeconomic research status and issues in clinical development of antimicrobial agents

Hiroyuki Sakamaki, Naobumi Ishida, Shunya Ikeda, Shuichi Yajima, Noaki Ikegami

Research output: Contribution to journalArticle

Abstract

Questionnaires assessing the status, pharmacoeconomic research and the use of research results in Japan were sent to physicians and dentists belonging to the Japanese Society of Chemotherapy who are involved with clinical studies on antimicrobial agents and to pharmaceutical companies belonging to the Japan Antibiotics Research Association who are involved in the development of antimicrobial agents. The response rate were 58% for physicians and dentists (185 out of 317) and 65% for pharmaceutical companies (31 out of 48). The topic of pharmacoeconomics was of interest to 77% of the physicians and dentists who responded mainly because of its impact on the development of manuals for the use of antimicrobial agents, its impact on total medical expenditure in Japan, information on medical facility management and for making decisions regarding formulary control, etc. In contrast, only 23% of the pharmaceutical companies who responded had studied the pharmacoeconomics of antimicrobial agents. Most of the respondents regarded pharmacoeconomic parameters, such as the curative period for infectious diseases, hospital/ICU stay and patient QOL, to be of primary importance. Respondents also saw a need for pharmacoeconomic research on innovative antimicrobial agents, drugs allowing new administration methods and other types of drugs using the above parameters as a measure. We found that physicians, dentists, and pharmaceutical companies were well aware of the need to study the pharmacoeconomics of antimicrobial agents, but that several issues were hindering the implementation of studies, including guidelines for obtaining informed consent in pharmacoeconomics studies, procedures for concluding contracts for clinical studies, the lack of pharmacoeconomic research guidelines, and the scarcity of specialists in this area.

Original languageEnglish
Pages (from-to)538-546
Number of pages9
JournalJapanese Journal of Chemotherapy
Volume50
Issue number8
Publication statusPublished - 2002 Aug 1

Fingerprint

Pharmaceutical Economics
Anti-Infective Agents
Dentists
Research
Pharmaceutical Preparations
Physicians
Japan
Guidelines
Formularies
Contracts
Health Expenditures
Informed Consent
Communicable Diseases
Length of Stay
Decision Making
Anti-Bacterial Agents
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Sakamaki, H., Ishida, N., Ikeda, S., Yajima, S., & Ikegami, N. (2002). Pharmacoeconomic research status and issues in clinical development of antimicrobial agents. Japanese Journal of Chemotherapy, 50(8), 538-546.

Pharmacoeconomic research status and issues in clinical development of antimicrobial agents. / Sakamaki, Hiroyuki; Ishida, Naobumi; Ikeda, Shunya; Yajima, Shuichi; Ikegami, Noaki.

In: Japanese Journal of Chemotherapy, Vol. 50, No. 8, 01.08.2002, p. 538-546.

Research output: Contribution to journalArticle

Sakamaki, H, Ishida, N, Ikeda, S, Yajima, S & Ikegami, N 2002, 'Pharmacoeconomic research status and issues in clinical development of antimicrobial agents', Japanese Journal of Chemotherapy, vol. 50, no. 8, pp. 538-546.
Sakamaki, Hiroyuki ; Ishida, Naobumi ; Ikeda, Shunya ; Yajima, Shuichi ; Ikegami, Noaki. / Pharmacoeconomic research status and issues in clinical development of antimicrobial agents. In: Japanese Journal of Chemotherapy. 2002 ; Vol. 50, No. 8. pp. 538-546.
@article{e96bcb56921147f0b7b38db9985e117e,
title = "Pharmacoeconomic research status and issues in clinical development of antimicrobial agents",
abstract = "Questionnaires assessing the status, pharmacoeconomic research and the use of research results in Japan were sent to physicians and dentists belonging to the Japanese Society of Chemotherapy who are involved with clinical studies on antimicrobial agents and to pharmaceutical companies belonging to the Japan Antibiotics Research Association who are involved in the development of antimicrobial agents. The response rate were 58{\%} for physicians and dentists (185 out of 317) and 65{\%} for pharmaceutical companies (31 out of 48). The topic of pharmacoeconomics was of interest to 77{\%} of the physicians and dentists who responded mainly because of its impact on the development of manuals for the use of antimicrobial agents, its impact on total medical expenditure in Japan, information on medical facility management and for making decisions regarding formulary control, etc. In contrast, only 23{\%} of the pharmaceutical companies who responded had studied the pharmacoeconomics of antimicrobial agents. Most of the respondents regarded pharmacoeconomic parameters, such as the curative period for infectious diseases, hospital/ICU stay and patient QOL, to be of primary importance. Respondents also saw a need for pharmacoeconomic research on innovative antimicrobial agents, drugs allowing new administration methods and other types of drugs using the above parameters as a measure. We found that physicians, dentists, and pharmaceutical companies were well aware of the need to study the pharmacoeconomics of antimicrobial agents, but that several issues were hindering the implementation of studies, including guidelines for obtaining informed consent in pharmacoeconomics studies, procedures for concluding contracts for clinical studies, the lack of pharmacoeconomic research guidelines, and the scarcity of specialists in this area.",
author = "Hiroyuki Sakamaki and Naobumi Ishida and Shunya Ikeda and Shuichi Yajima and Noaki Ikegami",
year = "2002",
month = "8",
day = "1",
language = "English",
volume = "50",
pages = "538--546",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "8",

}

TY - JOUR

T1 - Pharmacoeconomic research status and issues in clinical development of antimicrobial agents

AU - Sakamaki, Hiroyuki

AU - Ishida, Naobumi

AU - Ikeda, Shunya

AU - Yajima, Shuichi

AU - Ikegami, Noaki

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Questionnaires assessing the status, pharmacoeconomic research and the use of research results in Japan were sent to physicians and dentists belonging to the Japanese Society of Chemotherapy who are involved with clinical studies on antimicrobial agents and to pharmaceutical companies belonging to the Japan Antibiotics Research Association who are involved in the development of antimicrobial agents. The response rate were 58% for physicians and dentists (185 out of 317) and 65% for pharmaceutical companies (31 out of 48). The topic of pharmacoeconomics was of interest to 77% of the physicians and dentists who responded mainly because of its impact on the development of manuals for the use of antimicrobial agents, its impact on total medical expenditure in Japan, information on medical facility management and for making decisions regarding formulary control, etc. In contrast, only 23% of the pharmaceutical companies who responded had studied the pharmacoeconomics of antimicrobial agents. Most of the respondents regarded pharmacoeconomic parameters, such as the curative period for infectious diseases, hospital/ICU stay and patient QOL, to be of primary importance. Respondents also saw a need for pharmacoeconomic research on innovative antimicrobial agents, drugs allowing new administration methods and other types of drugs using the above parameters as a measure. We found that physicians, dentists, and pharmaceutical companies were well aware of the need to study the pharmacoeconomics of antimicrobial agents, but that several issues were hindering the implementation of studies, including guidelines for obtaining informed consent in pharmacoeconomics studies, procedures for concluding contracts for clinical studies, the lack of pharmacoeconomic research guidelines, and the scarcity of specialists in this area.

AB - Questionnaires assessing the status, pharmacoeconomic research and the use of research results in Japan were sent to physicians and dentists belonging to the Japanese Society of Chemotherapy who are involved with clinical studies on antimicrobial agents and to pharmaceutical companies belonging to the Japan Antibiotics Research Association who are involved in the development of antimicrobial agents. The response rate were 58% for physicians and dentists (185 out of 317) and 65% for pharmaceutical companies (31 out of 48). The topic of pharmacoeconomics was of interest to 77% of the physicians and dentists who responded mainly because of its impact on the development of manuals for the use of antimicrobial agents, its impact on total medical expenditure in Japan, information on medical facility management and for making decisions regarding formulary control, etc. In contrast, only 23% of the pharmaceutical companies who responded had studied the pharmacoeconomics of antimicrobial agents. Most of the respondents regarded pharmacoeconomic parameters, such as the curative period for infectious diseases, hospital/ICU stay and patient QOL, to be of primary importance. Respondents also saw a need for pharmacoeconomic research on innovative antimicrobial agents, drugs allowing new administration methods and other types of drugs using the above parameters as a measure. We found that physicians, dentists, and pharmaceutical companies were well aware of the need to study the pharmacoeconomics of antimicrobial agents, but that several issues were hindering the implementation of studies, including guidelines for obtaining informed consent in pharmacoeconomics studies, procedures for concluding contracts for clinical studies, the lack of pharmacoeconomic research guidelines, and the scarcity of specialists in this area.

UR - http://www.scopus.com/inward/record.url?scp=0036696016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036696016&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 538

EP - 546

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 8

ER -